9PL Stock Overview
Develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GENinCode Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.047 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.038 |
| Beta | 0.76 |
| 11 Month Change | -1.05% |
| 3 Month Change | -38.16% |
| 1 Year Change | -31.39% |
| 33 Year Change | -88.37% |
| 5 Year Change | n/a |
| Change since IPO | -89.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9PL | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.4% | 0.2% | 0.8% |
| 1Y | -31.4% | 13.9% | 8.6% |
Return vs Industry: 9PL underperformed the German Healthcare industry which returned 13.9% over the past year.
Return vs Market: 9PL underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 9PL volatility | |
|---|---|
| 9PL Average Weekly Movement | 6.8% |
| Healthcare Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9PL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9PL's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 42 | Matthew Walls | www.genincode.com |
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company’s molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.
GENinCode Plc Fundamentals Summary
| 9PL fundamental statistics | |
|---|---|
| Market cap | €9.03m |
| Earnings (TTM) | -€7.13m |
| Revenue (TTM) | €3.12m |
2.9x
P/S Ratio-1.3x
P/E RatioIs 9PL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9PL income statement (TTM) | |
|---|---|
| Revenue | UK£2.60m |
| Cost of Revenue | UK£1.31m |
| Gross Profit | UK£1.29m |
| Other Expenses | UK£7.23m |
| Earnings | -UK£5.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 49.44% |
| Net Profit Margin | -228.70% |
| Debt/Equity Ratio | 0% |
How did 9PL perform over the long term?
See historical performance and comparison